The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells

Cancer Research

Volumn 63, Issue 15, 2003, Pages 4450-4459

  Barbacci, E Gabriella ^a   Pustilnik, Leslie R ^a   Rossi, Ann Marie K ^a   Emerson, Erling ^a   Miller, Penny E ^a   Boscoe, Brian P ^a   Cox, Eric D ^a   Iwata, Kenneth K ^b   Jani, Jitesh P ^a   Provoncha, Kathleen ^b   Kath, John C ^a   Liu, Zhengyu ^a   Moyer, James D ^a,c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b OSI PHARMACEUTICALS INC   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CP 654577; ERLOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT EPIDERMAL GROWTH FACTOR; UNCLASSIFIED DRUG; VALINOMYCIN;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN 3T3; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING; XENOGRAFT;

3T3 CELLS; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0042591422     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Yarden, Y., and Sliwkowski, M. X. Untangling the erbB signalling network. Mol. Cell. Biol., 2: 127-137, 2001.
2. Hynes, N. E., and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198: 165-184, 1994.
3. Prigent, S. A., and Lemoine, N. R. The Type-I (EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res., 4: 1-24, 1992.
4. Baselga, J., and Mendelsohn, J. Type I receptor tyrosine kinases as targets for therapy in breast cancer. J. Mammary Gland Biol. Neoplasia, 2: 165-174, 1997.
5. Slichenmyer, W., and Fry, D. W. Anticancer therapy targeting the ErbB family of receptor tyrosine kinases. Semin. Oncol., 28 (Suppl. 16): 67-79, 2001.
6. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer, 8: 3-9, 2001.
7. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin. Oncol., 26: 78-83, 1999.
8. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eierman, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Eng. J. Med., 344: 783-792, 2001.
9. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., and Stewart, S. J. First-Line Herceptin® monotherapy in metastatic breast cancer. Oncology, 61 (Suppl. 2): 37-42, 2001.
10. Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, V., Waksal, H., and Mendelsohn, J. Phase 1 studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol., 18, 904-914, 2000.
11. Ciardiello, F., and Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 7: 2958-2970, 2001.
12. Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A., DiOrio, C., Doty, J. Morin, M. J., Moyer, M. P., Neveu, M., Pollack, V. A., Pustilnik, L. R., Reynolds, M. M., Sloan, D., Theleman, A., and Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inbibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 57: 4838-4848, 1997.
13. Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., Vaidya, M. P., Arnold, L. D., Doty, J. L., Iwata, K. K., and Morin, M. J. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exper. Ther., 291: 739-748, 1999.
14. Perez-Soler, R., Chachoua, A., Huberman, M., Karp, D., Rigas, J., Hammond, L., Rowinsky, E., Preston, G., Ferrante, K., Allen, L. F., Nadler, P. I., and Bonomi, P. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced EGFR-expressing nonsmall cell cancer. Proc. Am. Soc. Clin. Oncol., 20: 310a, 2001.
15. Ciardello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., DePlacido, S., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000.
16. Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., and Arteaga, C. L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res., 61: 8887-8895, 2001.
17. Woodburn, J., Kendrew, J., Fennell, M., Kelly, H., and Wakeling, A. ZD1839 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): correlation of c-fos expression and tumor growth inhibition. Proc. Am. Assoc. Cancer Res., 41: 406, 2000.
18. Tsou, H-W, Mamuya, N., Johnson, B. D., Reich, M. F., Gruber, B. C., Ye, F., Nilakantan, R., Shen, R., Discafani, C., DeBlanc, R., Davis, R., Koehn, F. E., Greenberger, L. M., Wang, Y-F., and Wissner, A. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem., 44: 2719-2734, 2001.
19. Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., McNamara, D. J., Nelson, J. M., Sherwood, V., Smaill, J. B., Trumpp-Kallmeyer, S., and Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Nat. Acad. Sci., USA. 95: 12022-12027, 1999.
20. Colomer, R., Lupu, R., Bacus, S. S., and Gelmann, E. P. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br. J. Cancer, 70: 819-825, 1994.
21. Lewis, G. D., Figari, I., Fendly, B., Wong, W. L., Carter, P., Gorman, C., and Shepard, H. M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother., 37: 255-263, 1993.
22. Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., and Ullrich, A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
23. 1 cell cycle regulators in breast tumour cells. Oncogene, 19: 1647-1656, 2000.
24. Kath, J. C., Tom, N. J., Cox, E. D., and Bhattacharya, S. K. Preparation of aminoquinazolines and related compounds as anticancer drugs. Eur. Pat. Appl., EP 1029853, 2000.
25. Faziloi, F., Kim, U-H., Rhee, S. G., Molloy, C. J., Segatto, O., and DiFiore, P. P. The erbB-2 mitogenic signalling pathway: tyrosine phosphorylation of phospholipase C-g and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Mol. Cell. Biol., 11: 2040-2048, 1991.
26. Cohen, B. D., Goldstein, D. J., Rutledge, L., Vass, W. C., Lowy, D. R., Schlegel, R., and Schiller, J. T. Transformation specific interaction of the bovine papilomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain. J. Virol., 67: 5303-5311, 1993.
27. Association for Assessment and Accreditation of Laboratory Animal Care. Guide for the Care and Use of Laboratory Animals, Ed. 6. National Academy Press. Washington D. C., 1996.
28. Brockhoff, G., Heisz, P., Schlegel, J., Hofstaedter, F., and Knueechel, R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry, 44: 338-348, 2001.
29. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
30. Wilkinson, M. G., and Millar, J. B. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J., 14: 2147-2157, 2000.
31. Roh, H., Pippin, J., and Drebin, J. A. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res., 60: 560-565, 2000.
32. Zhou, B. P., Hu, M. C-T., Miller, S. A., Yu, Z., Xia, W., Lin, S.-Y, and Hung, M-C. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J. Biol. Chem., 275: 8027-8031, 2000.
33. Roh, H., Pippin, J. A., Green, D. W., Boswell, C. B., Hirose, C. T., Mokadam, N., and Drebin, J. A. HER2/neu antisense targeting of human breast carcinoma. Oncogene, 19: 6138-6143, 2000.
34. Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. C., Posner, R. H., Nau, M. N., Dennis, P. A., and Lipkowitz, S. Down-regulation of the erbB2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB2. Cancer Res., 61: 4892-4900, 2001.
35. Traxler, P., Bold, G., Buchdunger, E., Caravatti, G., Furet, P., Manley, P., O'Reilly, T., Wood, J., and Zimmermann, J. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev., 21: 499-512, 2001.
36. Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C., Harris, R., Page, M., Smith, K. J., Guntrip, S. B., Carter, M. C., Shaw, R. J., Jowett, A., Stables, J., Topley, P., Wood, E. R., Brignola, P. S., Kadwell, S. H., Reep, B. R., Mullin, R. J., Alligood, K. J., Keith, B. R., Crosby, R. M., Murray, D. M., Knight, W. B., Gilmer, T. M., and Lackey, K. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res., 61: 7196-7203, 2001.
37. Brignola, P. S., Lackey, K., Kadwell, S. H., Hoffman, C., Horne, E., Carter, H. L., Stuart, J. D., Blackburn, K., Moyer, M. P., Alligood, K. J., Knight, W. B., and Wood, E. R. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. J. Biol. Chem., 277: 1576-1585, 2002.
38. Egeblad, M., Mortensen, O. H., van Kempen, L. C., and Jaattela, M. BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations. Biochem. Biophys. Res. Commun., 281: 25-31, 2001.
39. Lenferink, A. E. G., Busse, D., Flanagan, W. M., Yakes, F. M., and Arteaga, C. L. ErbB2/neu kinase modulates cellular p27Kip1 and cyclin D1 through multiple signaling pathways. Cancer Res., 61: 6583-6591, 2001.
40. Sliwkowski, M. X., Lofgren, J. A., Lewis, G. D., Hotaling, T. E., Fendly, B. M., and Fox, J. A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol., 26: 60-70, 1999.
41. Le, X. F., McWatters, A., Wiener, J., Wu, J. Y., Mills, G. B., and Bast, R. C., Jr. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin. Cancer Res., 6: 260-270, 2000.
42. Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., and Hynes, N. E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor over-expression does not determine growth dependency. Mol. Cell. Biol., 20: 3210-3223, 2000.
43. Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., Seelig, S., and Arteaga, C. L. Herceptin-induced inhibition of phosphatidylinositol-3-kinase and Akt is required for antibody-mediated effects on p27, cyclin D1 and antitumor action. Cancer Res., 62: 4132-4141, 2002.
44. Diehl, J. A., Cheng, M., Roussel, M. F., and Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12: 3499-3511, 1998.
45. Pinkus-Kramarski, R., Soussa, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., and Yarden, Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J., 15: 2452-2467, 1996.